MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555907 | Name: SB-201076

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB-201076 is a potent ATP citrate-lyase inhibitor. SB-204990 is the prodrug of SB-201076.

Chemical Structure

SB-201076
SB-201076
CAS#154566-05-9

Theoretical Analysis

MedKoo Cat#: 555907

Name: SB-201076

CAS#: 154566-05-9

Chemical Formula: C18H24Cl2O6

Exact Mass: 406.0950

Molecular Weight: 407.28

Elemental Analysis: C, 53.08; H, 5.94; Cl, 17.41; O, 23.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SB-201076; SB 201076; SB201076;
IUPAC/Chemical Name
(S)-(3R*,5S*)-3-Carboxy-11-(2,4-dichlorophenyl)-3,5-dihydroxyundecanoic Acid
InChi Key
NPZOIISFQXTCQN-KDOFPFPSSA-N
InChi Code
InChI=1S/C18H24Cl2O6/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14(21)10-18(26,17(24)25)11-16(22)23/h7-9,14,21,26H,1-6,10-11H2,(H,22,23)(H,24,25)/t14-,18+/m1/s1
SMILES Code
O=C(O)C[C@](O)(C(O)=O)C[C@H](O)CCCCCCC1=CC=C(Cl)C=C1Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 407.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sanfilippo J, Ness M, Petscher Y, Rappaport L, Zuckerman B, Gaab N. Reintroducing Dyslexia: Early Identification and Implications for Pediatric Practice. Pediatrics. 2020 Jul;146(1):e20193046. doi: 10.1542/peds.2019-3046. Epub 2020 Jun 23. PMID: 32576595; PMCID: PMC7329249. 2: Feng X, Zhang L, Xu S, Shen AZ. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. Prog Lipid Res. 2020 Jan;77:101006. doi: 10.1016/j.plipres.2019.101006. Epub 2019 Sep 6. PMID: 31499095. 3: Birchenall KA, Welsh GI, López Bernal A. Metabolite Changes in Maternal and Fetal Plasma Following Spontaneous Labour at Term in Humans Using Untargeted Metabolomics Analysis: A Pilot Study. Int J Environ Res Public Health. 2019 Apr 30;16(9):1527. doi: 10.3390/ijerph16091527. PMID: 31052173; PMCID: PMC6539865. 4: Zhang C, Liu J, Huang G, Zhao Y, Yue X, Wu H, Li J, Zhu J, Shen Z, Haffty BG, Hu W, Feng Z. Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev. 2016 Sep 1;30(17):1956-70. doi: 10.1101/gad.283283.116. PMID: 27664236; PMCID: PMC5066239. 5: Inoue N, Watanabe H, Okamura K, Kondo S, Kagami S. Are the equations for the creatinine-based estimated glomerular filtration rate applicable to the evaluation of renal function in Japanese children and adult patients receiving chemotherapy? Clin Exp Nephrol. 2015 Apr;19(2):298-308. doi: 10.1007/s10157-014-0976-z. Epub 2014 May 4. PMID: 24792810. 6: Chu KY, Lin Y, Hendel A, Kulpa JE, Brownsey RW, Johnson JD. ATP-citrate lyase reduction mediates palmitate-induced apoptosis in pancreatic beta cells. J Biol Chem. 2010 Oct 15;285(42):32606-15. doi: 10.1074/jbc.M110.157172. Epub 2010 Aug 7. PMID: 20693577; PMCID: PMC2952263. 7: Yang L, Wang DX, Zheng QY, Pan J, Huang ZT, Wang MX. Highly efficient and concise synthesis of both antipodes of SB204900, clausenamide, neoclausenamide, homoclausenamide and zeta-clausenamide. Implication of biosynthetic pathways of Clausena alkaloids. Org Biomol Chem. 2009 Jun 21;7(12):2628-34. doi: 10.1039/b901965k. Epub 2009 May 5. PMID: 19503939. 8: Yoo B. Impact of missing data on type 1 error rates in non-inferiority trials. Pharm Stat. 2010 Apr-Jun;9(2):87-99. doi: 10.1002/pst.378. PMID: 19408241. 9: Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005 Oct;8(4):311-21. doi: 10.1016/j.ccr.2005.09.008. PMID: 16226706. 10: Michno A, Skibowska A, Raszeja-Specht A, Cwikowska J, Szutowicz A. The role of adenosine triphosphate citrate lyase in the metabolism of acetyl coenzyme a and function of blood platelets in diabetes mellitus. Metabolism. 2004 Jan;53(1):66-72. doi: 10.1016/j.metabol.2003.07.012. PMID: 14681844. 11: Pearce NJ, Yates JW, Berkhout TA, Jackson B, Tew D, Boyd H, Camilleri P, Sweeney P, Gribble AD, Shaw A, Groot PH. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998 Aug 15;334 ( Pt 1)(Pt 1):113-9. doi: 10.1042/bj3340113. PMID: 9693110; PMCID: PMC1219669. 12: van Vlijmen BJ, Pearce NJ, Bergö M, Staels B, Yates JW, Gribble AD, Bond BC, Hofker MH, Havekes LM, Groot PH. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. Arzneimittelforschung. 1998 Apr;48(4):396-402. PMID: 9608883.

View History

NS6180

NS6180

New Featured